Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 2
1993 16
1994 9
1995 11
1996 13
1997 12
1998 9
1999 16
2000 37
2001 77
2002 54
2003 113
2004 144
2005 163
2006 183
2007 203
2008 202
2009 202
2010 219
2011 186
2012 175
2013 145
2014 127
2015 142
2016 135
2017 128
2018 130
2019 108
2020 115
2021 103
2022 99
2023 81
2024 85
2025 85
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,228 results

Results by year

Filters applied: . Clear all
Page 1
Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs.
Parlakpinar H, Gunata M. Parlakpinar H, et al. Immunopharmacol Immunotoxicol. 2021 Dec;43(6):651-665. doi: 10.1080/08923973.2021.1966033. Epub 2021 Aug 20. Immunopharmacol Immunotoxicol. 2021. PMID: 34415233 Review.
Immunosuppressive drugs used in the transplantation period are generally defined as induction and maintenance therapy. The use of immunosuppressants, which are particularly useful and have fewer side effects, decreased both mortality and morbidity. Many drugs …
Immunosuppressive drugs used in the transplantation period are generally defined as induction and maintenance therapy. The use of imm …
Side effects of sirolimus.
Merkel S, Mogilevskaja N, Mengel M, Haller H, Schwarz A. Merkel S, et al. Transplant Proc. 2006 Apr;38(3):714-5. doi: 10.1016/j.transproceed.2006.01.044. Transplant Proc. 2006. PMID: 16647452
The mTOR inhibitor sirolimus improves renal transplant function compared with the nephrotoxic calcineurin inhibitors. We evaluated retrospectively the adverse events in 119 of 134 patients getting sirolimus which seemed to be caused by sirolimus …
The mTOR inhibitor sirolimus improves renal transplant function compared with the nephrotoxic calcineurin inhibitors. We evalu …
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant …
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kid …
Sirolimus--challenging current perspectives.
Buhaescu I, Izzedine H, Covic A. Buhaescu I, et al. Ther Drug Monit. 2006 Oct;28(5):577-84. doi: 10.1097/01.ftd.0000245377.93401.39. Ther Drug Monit. 2006. PMID: 17038868 Review.
Also, a potentially benefit of this valuable drug in some immunologic and malignant diseases is currently under scrutiny.Classical side effects: hematological (anaemia, leucopenia, thrombocytopenia), hypercholesterolemia, arthralgias, extremity oedema and impaired w …
Also, a potentially benefit of this valuable drug in some immunologic and malignant diseases is currently under scrutiny.Classical side …
Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE. Nguyen LS, et al. Drug Saf. 2019 Jul;42(7):813-825. doi: 10.1007/s40264-019-00810-9. Drug Saf. 2019. PMID: 30868436 Review.
Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations. Experience in transplantation studies has been gained regarding the side effect pr …
Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical …
Management of side effects of sirolimus therapy.
Stallone G, Infante B, Grandaliano G, Gesualdo L. Stallone G, et al. Transplantation. 2009 Apr 27;87(8 Suppl):S23-6. doi: 10.1097/TP.0b013e3181a05b7a. Transplantation. 2009. PMID: 19384183
Although SRL has been suggested to reduce the progression of chronic renal graft damage and to prevent the development of neoplasia, two of the most prominent challenges in the field of transplantation, its use is significantly limited by an extremely high incidence of …
Although SRL has been suggested to reduce the progression of chronic renal graft damage and to prevent the development of neoplasia, two of …
Immunoregulation and tolerance.
Knechtle SJ. Knechtle SJ. Transplant Proc. 2010 Nov;42(9 Suppl):S13-5. doi: 10.1016/j.transproceed.2010.07.039. Transplant Proc. 2010. PMID: 21095443 Review.
Conditions that promote their development and enhance their biological function may be attractive for promoting unresponsiveness to organ transplants. Among the various mechanistic influences of sirolimus, one of its properties as an in vivo agent is to enhance Treg …
Conditions that promote their development and enhance their biological function may be attractive for promoting unresponsiveness to organ …
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.
Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. Morrisett JD, et al. J Lipid Res. 2002 Aug;43(8):1170-80. J Lipid Res. 2002. PMID: 12177161 Free article.
Sirolimus (Rapammune, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease. This study was undert …
Sirolimus (Rapammune, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipide …
Malignancy after transplantation.
Buell JF, Gross TG, Woodle ES. Buell JF, et al. Transplantation. 2005 Oct 15;80(2 Suppl):S254-64. doi: 10.1097/01.tp.0000186382.81130.ba. Transplantation. 2005. PMID: 16251858 Review.
In fact, it is expected that cancer will surpass cardiovascular complications as the leading cause of death in transplant patients within the next 2 decades. An understanding of the underlying pathobiology and how to minimize cancer risks in transplant recipients ar …
In fact, it is expected that cancer will surpass cardiovascular complications as the leading cause of death in transplant patients wi …
mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G, Ivani de Paula M, Rangel ÉB. Fernandes-Silva G, et al. Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):367-385. doi: 10.1080/17425255.2017.1239708. Epub 2016 Sep 28. Expert Opin Drug Metab Toxicol. 2017. PMID: 27659512 Review.
We summarize the nephrotoxic and diabetogenic mechanisms of mTORi after pancreas transplant, the alternatives to minimize these effects, and report on other adverse events. ...It is equally important to critically analyze clinical studies. Of importance, mini …
We summarize the nephrotoxic and diabetogenic mechanisms of mTORi after pancreas transplant, the alternatives to minimize these ef …
3,228 results